Diagnosis and Treatment of Severe COVID-19 Complicated with Spontaneous Pneumothorax: A Case Report

Ruibing Lyu, MD *, Xin Li, MD * *

* Department of PCCM, CR & WISCO General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, Hubei, China. Received March 30, 2020; revision received April 08, 2020; accepted April 09, 2020

Abstract: This case report describes a patient with severe coronavirus disease 2019 (COVID-19) concomitated with spontaneous pneumothorax, along with retrospective analysis of effective diagnosis and treatment. The case shows how chest radiography and computed tomography can play an important role in diagnosing and providing useful information for clinical management. The patient’s outcome and prognosis was related to his clinical management. In particular, early comprehensive treatment was certainly key to reducing complications and mortality in severe novel coronavirus pneumonia.

Key words: COVID-19; Spontaneous pneumothorax; CT scan; Diagnosis; Treatment.

Advanced Ultrasound in Diagnosis and Therapy 2020;02:142-146 DOI: 10.37015/AUDT.2020.200019

Coronavirus is a type of enveloped RNA virus that is widely distributed in humans, other mammals, and birds. The infection of coronavirus can cause respiratory, intestinal, liver, and nervous system diseases [1,2]. A group of patients with unexplained pneumonia were reported in December 2019, all of whom had exposure in the wholesale seafood market at Wuhan, China. When these patients were tested, unbiased sequencing of samples from the patients with pneumonia detected a previously unknown β coronavirus that was afterwards named SARS-CoV-2. Here, we present a case report for a patient with severe coronavirus disease 2019 (COVID-19) concomitated with spontaneous pneumothorax along with analysis of effective diagnosis and treatment retrospectively.

Case study

Patient characteristics

The patient was a 38-year-old man, 180cm height, and 82 kg weight. He complained of fever for 11 days and cough for 3 days. Though he claimed no history of interaction with the South China seafood market, however, he had a meal with colleagues recently. He smoked and drank for years and was allergic to levofloxacin. Physical examination found the following: body temperature 37 °C, heart rate 85 beats/min, breathing 22 beats/min, blood pressure 130 / 80mmHg, and finger oxygen saturation 87% (without oxygen inhalation). Chest radiographs were performed on January 16, January 27, and February 8. (Fig. 1A). Blood analysis was normal and influenza virus test was negative. The patients was admitted to the hospital on January 22, 2020.

Diagnosis and treatment

On admission, the patient was provided continuous nasal inhalation of oxygen. On January 24, the nucleic acid test of his throat swab was positive. One day later, the patient showed dyspnea at night, so a high-flow nasal canula (temperature 31° C, flow 50 L/min, oxygen concentration 80%) was administrated. Patient symptoms were alleviated subsequently, and the SPO2 increased to 91%.

* Corresponding author: Department of PCCM, CR & WISCO General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, Hubei, China
  e-mail: 13667163168@139.com

2576-2508©AUDT 2020 • http://www.AUDT.org
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
But on January 26, the patient’s biochemical indicators changed (Table 1), and the chest radiograph showed double lung membrane vitreous shadow (Fig. 1B). Thus, the antivirals (ganciclovir, oseltamivir) and hormones were replaced with abidol (0.2 g, p.o., TID), and meropenem (1.0 g, IVGTT, Q 12 h) plus azithromycin (0.25 g, p.o., Q d). Medications that promote the absorption of inflammatory factors (50 ml, xuebijing, IVGTT, Q 12 h), phlegm and antifibrosis (acetylcysteine effervescent, Jinkang Suoli, 0.6 g, p.o., TID) were prescribed as well.

The patient’s signs were mostly stable from January 26 to February 1, and the nucleic acid test of his throat swab was negative on January 31. However, on February 4 the patient complained of pain in his right anterior chest, with an aggravated irritating dry cough. Meanwhile, palpitation and dyspnea occurred after minor activity. Therefore, the biochemical indicators (Table 1), chest radiograph (Fig. 1C), and chest CT were re-examined. Compared the admission CT (Fig. 2A), the CT (Fig. 2B) showed the lung infection had worsened and lung tissue was compressed by 30%. The treatment methods were adjusted accordingly, including reducing activity, adjusting parameters of oxygen inhalation, prescribing anti-infection medication (piracillin sodium 2.5 g, Yijun, IVGTT, Q 12 h), reintroducing methylprednisolone sodium succinate and doxofylline infusion to relieve hyperresponsiveness, adding long-acting beta-receptor agonist plus hormone inhalant (salmeterol tikasone, sulide, 50/500 μg), and preventing deep vein thrombosis (Enoxaparin Sodium, Kesai, 4000 u, subcutaneous injection). Although the nucleic acid test of pharyngeal swab was positive on February 6, three consecutive subsequent re-examinations of the nucleic acid test were negative on February 14, 19, and 22. The chest CT results showed significant improvement (Fig. 2C). Then the patient was discharged on February 24.

**Figure 1** Chest X-ray findings. (A) On January 16, the texture of both lungs was enhanced and blurred, and it was recommended to re-examine after treatment; (B) On January 27, the texture of both lungs became thicker, increased, blurred, and the patch-like blur was seen in the outer band of the lesion; bilateral hilar flocculation, suggesting infectious lesions in both lungs, and possible viral pneumonia; (C) On February 8, the texture of both lungs became thicker and thicker, scattered in patchy and flocculent blurs, with blurred edges, and the left lung field tissue was compressed by about 30%; considering the left pneumothorax, bilateral lung infection, and the lesions progressed.

**Discussion**

The coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by SARS-CoV-2. The types of novel coronavirus pneumonia (NCP) that it causes are classified as light, normal, severe, and critical, according to the disease severity. Patients with COVID-19 mainly manifest with fever, cough, and dyspnea [3]. Severe patients usually present with dyspnea and/or hypoxemia after 1 week of onset, and progress rapidly to acute respiratory distress syndrome and coagulation dysfunction [4]. The patient in this present case report showed that as the bilateral lung infection became gradually aggravated on CT (Fig. 1, 2), indicators of laboratory examination (Table 1) further suggested the same progression, with myocardial and liver damage as well.

This patient was diagnosed with severe NCP based on epidemiology, clinical symptoms, imaging, and nucleic acid test. After admission, he presented with acute hypoxic respiratory failure, and the oxygenation index was less than 200. He was given high-flow nasal canula (HFNC), which was better adaptable to him compared with the ordinary non-invasive ventilator [5]. However, the patient developed spontaneous pneumothorax, which might be related to deep airway and alveolar damage caused by COVID-19 virus infection, especially the distal alveoli with mucus-like exudation [6]. The pathology of NCP mainly shows the exudation of monocytes and macrophages, vascular congestion, and edema in the alveolar septum, with the formation of transparent thrombus in the blood vessels [7]. Based on pulmonary fibrosis caused by inflammation, bronchioles...
are narrow and distorted, and the valve mechanism could cause pulmonary bullae. Increased intrapulmonary pressure, such as coughing, may lead to bullae rupture and secondary pneumothorax. Continuous use of HFNC can increase PO2 in the blood and decrease the nitrogen pressure (P N). Increasing the P N difference between the pleural cavity and the blood will help the transfer of nitrogen from the pleural cavity to the blood, and accelerate lung recruitment consequently (Fig. 2F) [8]. For the patient with refractory and irritating dry cough, the dry-powder inhaler (DPI), or the quantitative inhalation combined with aerosol storage tank (long-acting β2 receptor agonist) plus hormone (sulide, 50/500 μg) may reduce the airway hyperresponsiveness and improve airway spasm [9]. Acetylcysteine effervescent is beneficial for pulmonary rehabilitation due to its antioxidant, anti-inflammatory and immunomodulatory effects, as well [10].

Several useful lessons could be obtained from the diagnosis and treatment of this case. Firstly, the cluster-onset is the main incentive (colleagues occurred who dined together developed similar symptoms. Secondly, some long-term lifestyle behaviors may increase susceptibility to the infection. Thirdly, the main signs and symptoms include fever, irritating dry cough, fatigue and dyspnea. Fourth, arterial blood gas analysis indicated acute respiratory failure, and 2019-nCoV nucleic acid test was positive in respiratory secretions.
As the disease worsens, multiple ground-glass-like lung may be observed, and are more predominant in the extrapulmonary bands [7], and even concomitant pneumothorax. Last, HFNC provides stable and high oxygen concentration to improve oxygenation compared with non-invasive ventilator. Reaching or exceeding the patient’s maximum inspiratory flow rate of active inhalation could reduce inhalation resistance, respiratory burden, and oxygen consumption. Humidification reduces the consumption of heat and water in patients with respiratory distress, maintains the airway mucous ciliary function at an optimal state, and facilitates drainage of secretions. It also provides a certain level of positive airway pressure and opens alveoli to prevent infections. In addition, HFNC does not require a completely closed circuit or exert obvious facial pressure, thus patient compliance is satisfactory. In addition, administration of high airflow washes the dead cavity of the upper airway to improve patient ventilation [11] and promote lung recruitment in ways that could efficiently benefit patients.

Table 1  Laboratory test results

| Item/Date          | January 22 | January 26 | January 29 | February 04 | February 08 | February 13 |
|--------------------|------------|------------|------------|-------------|-------------|-------------|
| Leukocyte count (×10⁹/L) | 6.69       | 14.43      | 13.03      | 9.12        | 11.9        | 9.57        |
| Blood platelet (×10⁹/L)    | 198.00     | 278.00     | 284.00     | 255.00      | 319.00      | 455.00      |
| Neutrophilic leukocytes (%) | 80.60      | 91.40      | 86.60      | 79.00       | 76.30       | 54.70       |
| Lymphocyte (×10⁹/L)        | 0.81       | 0.81       | 1.03       | 1.16        | 1.83        | 3.26        |
| Direct bilirubin (umol/L)  | 6.10       | 7.80       | 13.40      | 5.00        | 4.90        | 2.20        |
| Alamine aminotransferase (U/L) | 99.00      | 183.00     | 112.00     | 85.00       | 80.00       | 72.00       |
| Alkaline phosphatase (U/L) | 68.00      | 165.00     | 149.00     | 144.00      | 165.00      | 115.00      |
| γ-glutamyltranspeptidase (U/L) | 351.00     | 404.00     | 311.00     | 192.00      | 249.00      | 152.00      |
| α-Hydroxybutyrate Dehydrogenase (U/L) | 283.00     | 278.00     | 228.00     | 177.00      | 149.00      | 244.00      |
| Acetic dehydrogenase (U/L)  | 406.00     | 368.00     | 261.00     | 229.00      | 207.00      | 286.00      |
| C-Reactive Protein (mg/L)  | 67.04      | 36.94      | 30.85      | 42.76       | 56.49       | 3.85        |
| PCT (ng/ml)                | 0.02       | <0.02      | <0.02      | 0.02        | <0.02       | <0.02       |
| D-Dimer (mg/L)             | 0.16       | 1.10       | 1.70       | 1.73        | 2.71        | 2.17        |
| Arterial PH                | 7.43       | 7.43       | 7.45       | 7.46        | 7.44        | 7.44        |
| Pao₂ (mmHg)                | 57.00      | 84.00      | 73.00      | 75.00       | 84.00       | 110.00      |
| Oxygenation index          | 139.00     | 105.00     | 91.00      | 114.00      | 140.00      | 314.00      |

Conclusion
Nucleic acid testing should be carried out to identify the COVID-2019 in patients with a clear history of interaction with the epidemic area, acute onset of severe systemic symptoms unmatched with laboratory results, acute respiratory failure suggested by rapid chest CT imaging, and arterial blood gas analysis, as well as to exclude the possibility of other pneumonias. Early definitive diagnosis and comprehensive treatment of COVID-2019 can lessen complications and mortality.

Conflicts of Interest
All authors concur with the submission and have no conflicts of interest related to this work.

References
[1] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395: 809-815.
[2] Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care 2020; 24: 108.
[3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382: 1199-1207.
[4] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical
characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; e201585.

[5] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat Rev Drug Discov* 2020; 19: 149-150.

[6] Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *J Med Virol* 2020; 92: 491-494.

[7] National Health Commission. Diagnosis and treatment of novel coronavirus pneumonia (version 7). 2020-03-03.

[8] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. *Mil Med Res* 2020; 7: 11.

[9] Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. *Infection* 2020; 48: 155-163.

[10] Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care* 2020; 24: 108.

[11] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al; China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J* 2020; 2000547.